Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
The research study is testing a potential new treatment for bladder and urothelial cancer.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with IPF
An Investigation of the effects of Photobiomodulation (PBM) therapy on Pain and functional Mobility in people with knee osteoarthritis not awaiting knee replacement surgery (a pilot study with wait-list control)
A clinical trial to assess the safety of an experimental device implanted under the scalp for continuous recording of brain electrical activity associated the epileptic seizures
Trial Status:
Active, not recruiting
|
The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating your cancer when combined with other cancer drugs, compared to the standard of care for people with breast cancer.
The purpose of this study is to compare the effects, good or bad of an investigational product, inavolisib, when combined with palbociclib and fulvestrant. In this study, you will get either inavolisib or placebo and no one (you, your doctors, or the company sponsoring this study) will know who is receiving inavolisib and who is receiving placebo. This helps to ensure that the results are free from bias.
This study is trialing a novel anti-epileptic medication called XEN1101 in patients who suffer from primary generalized tonic-clonic seizures and have not achieved satisfactory seizure control using standard therapies.
The research project is testing a potential new treatment for nccRCC, called XL092 in a combination with nivolumab.
This study is trialing a novel anti-epileptic medication called XEN1101 in focal epilepsy patients who have not achieved satisfactory seizure control on at least two anti-epileptic medications.
A clinical trial of Ozanimod for treatment for Crohn’s Disease
Trial Status:
Active, not recruiting
|